Related Experiment Video

Updated: Jan 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis

Monica Margoni1,2, Francesca Rinaldi1, Silvia Miante1

  • 1Multiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Italy.

Multiple Sclerosis Journal - Experimental, Translational and Clinical
|September 27, 2019
PubMed

Insights

This study found that natalizumab followed by alemtuzumab is a safe and effective treatment for pediatric multiple sclerosis, maintaining no evidence of disease activity. Few mild reactions occurred, with no severe adverse events reported.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Pediatric-onset multiple sclerosis (MS) requires effective and safe treatment options.
  • Disease-modifying therapies are crucial for managing pediatric MS progression.

Purpose of the Study:

  • To evaluate the safety and efficacy of a natalizumab-to-alemtuzumab treatment switch in pediatric MS patients.
  • To assess infusion-associated reactions, severe adverse events, and disease activity status.

Main Methods:

  • A cohort of five pediatric MS patients (ages 16-17) was followed for a median of 3.9 years.
  • Patients received natalizumab, then switched to alemtuzumab after a mean of 25.6 infusions.
  • Safety and disease activity (no evidence of disease activity 3) were monitored.

Main Results:

  • Few mild to moderate infusion-associated reactions were observed during alemtuzumab infusions.
  • No severe adverse events were detected throughout the study period.
  • All patients maintained their no evidence of disease activity 3 status during follow-up.

Conclusions:

  • The therapeutic course of natalizumab followed by alemtuzumab is well-tolerated in pediatric MS.
  • This treatment strategy effectively maintains disease control in young patients with multiple sclerosis.

Keywords:
Alemtuzumabnatalizumabpediatric onset multiple sclerosis

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K